JPRN-UMIN000047753已完成Unknown
A single-center, randomized, two-arm study to identify effective nursing support from conception through implementation of a "program to increase self-efficacy with regard to parenting for parents" for pregnant couples expecting their first child. - Study to increase self-efficacy with respect to parenting to parents.
试验速览
- 阶段
- Unknown
- 状态
- 已完成
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 40years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Exclusion criteria will include couples with an abnormal pregnancy course, physical or mental disabilities, fetal complications, multiple pregnancies, inability to give consent for this research study, or plans to move to a distant location, making it difficult to conduct interviews. If an unexpected situation occurs after delivery, and the child has a serious illness or is admitted to the NICU, or if a serious situation arises that delays the mother's postpartum recovery, she will be excluded at that time.
研究者
相似试验
已完成
4 期
a study to evaluate the role of vitamin-D supllementation in teatment of patints with type 2 diabetesCTRI/2012/10/003059Abbott Healthcare Pvt Ltd110
进行中（未招募）
1 期
A clinical trial to evaluate treatment with a drug called secukinumab inadult patients who are diagnosed with moderate to severe hidradenitissuppurativa (long term skin disease characterized by the occurrence ofinflamed and swollen lumps)hidradenitis suppurativaEUCTR2018-002062-39-CZovartis Pharma AG541
进行中（未招募）
1 期
A clinical trial to evaluate treatment with a drug called secukinumab in adult patients who are diagnosed with moderate to severe hidradenitis suppurativa (long term skin disease characterized by the occurrence of inflamed and swollen lumps)MedDRA version: 20.0Level: LLTClassification code 10020041Term: Hidradenitis suppurativaSystem Organ Class: 100000004858hidradenitis suppurativaEUCTR2018-002062-39-DKovartis Pharma AG541
已完成
3 期
Study of efficacy and safety of two secukinumab dose regimens in subjects with moderate to severe hidradenitis suppurativaHidradenitis SuppurativaJPRN-jRCT2080224602ovartis Pharma. K.K.541
进行中（未招募）
1 期
A clinical trial to evaluate treatment with a drug called secukinumab inadult patients who are diagnosed with moderate to severe hidradenitissuppurativa (long term skin disease characterized by the occurrence ofinflamed and swollen lumps)hidradenitis suppurativaMedDRA version: 20.0Level: LLTClassification code 10020041Term: Hidradenitis suppurativaSystem Organ Class: 100000004858EUCTR2018-002063-26-BEovartis Pharma AG541